Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Roche exits epigenetic drug deal
Latest NewsAfter 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.
Ablynx adds Sanofi to its list of pharma partners
Latest NewsBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Shire licensed bispecific antibody from Novimmune
Latest NewsSwiss biopharmaceutical company Novimmune grants pharma company Shire a worldwide license to develop and commercialise a pre-clinical bispecific antibody candidate for haemophilia A.
One cell, many discoveries
ProductsBe ready for the next generation of cell analysis and isolation with BD FACSMelody.
UK invests £86m in healthcare SMEs
Latest NewsThe UK government has set up a new fund to support medical innovation. Breakthrough innovations that have the potential to benefit the NHS will also undergo accelerated access review aimed at speeding up access to novel medicines.
German PEI limits use of daclizumab
Latest NewsFollowing a safety warning of the EMA on deaths related to Biogens multiple scleroisis (MS) drug Zinbryta (daclizumab), German regulatory authority has issued a red hand letter.
Microbiome shows COPD subtypes
Latest NewsGerman researchers have found that the lung microbiome is indicative for different subtypes of chronic obstructive pulmonary disease (COPD).
Psoriasis: FDA approves guselkumab
Latest NewsThe Food and Drug Administration has granted US market approval to Janssen Biotech/MorphoSys IL23 blocker guselkumab (Temfya) as therapy for moderate to severe psoriasis.
ODAC greenlights Novartis CAR-T cell therapy CTL019
Latest NewsSwiss Novartis is about to receive the very first market approval (BLA) for a CAR-T cell cancer therapy globally. The FDAs Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019 (tisagenlecleucel) for the treatment of the orphan B-cell blood cancer ALL.
Enterome and Nestlé form JV
Latest NewsFrench gut microbiome analysis specialist Enterome Bioscience SA and therapeutic nutrition company Nestlé Health Science have formed a 50:50 joint venture aimed at developing microbiome-based diagnostics for certain common diseases.